AKT1 and metabolic dysfunction-associated steatotic liver disease: Despite our previous data showing that the IG of CF has the potential to decrease blood glucose through the PI3K-AKT signaling pathway [22], whether IG can protect mice from NAFLD is still far from elucidated.